Emiliangelo Ratti, PhD
R&D Strategic Advisor
Emiliangelo Ratti , PhD, serves as Research & Development Strategic Advisor at Orexia Therapeutics and was previously a Member of the Board. Emiliangelo was previously a Board member of GSK Spa in Italy, a member of the Research Committee of Farmindustria, the Italian national association of pharma industries, and a member of the Board of Tecnofarmaci, a consortium of Italian pharmaceutical industries for the development of pharmaceutical research.
Emiliangelo is a passionate and inspirational leader and a highly experienced pharmaceutical Research & Development executive with a proven track record of global executive leadership in drug discovery and clinical development in the neuroscience therapy area within major pharmaceutical companies (Glaxo, GlaxoWellcome, GlaxoSmithKline, PLC, and Takeda Pharmaceuticals Company, Ltd.) where he has held senior leadership roles in their Research & Development operations based in continental Europe, UK, USA, Japan and China.
Prior to Orexia, Emiliangelo was Senior Vice President and Global Head of the Neuroscience Therapeutic Area Unit at Takeda and member of the Research & Development Management Committee. He led expansion of the Neuroscience Therapeutic Area strategy and built a highly competitive and innovative neuroscience portfolio for the treatment of diseases in both psychiatry (treatment resistant depression and schizophrenia) and neurology (Parkinson’s and Alzheimer’s) as well as a cluster of rare neurological diseases (Narcolepsy, ALS, Epileptic Encephalopathies, and Kabuki syndrome) with therapies based on small molecules, antisense oligonucleotides and gene therapy.
Earlier, Emiliangelo was Founder and Chief Executive Officer of NeRRe Therapeutics, Ltd., a biotech spin-out company from GlaxoSmithKline (GSK), which focused on clinical development of a portfolio of neurokinin antagonists, a field in which he is a recognized expert. Prior to this position, Emiliangelo was Senior Vice President, Global Head of the Neurosciences Centre of Excellence for Drug Discovery at GSK and member of the company’s Research & Development Scientific Advisory Board and was appointed Managing Director of GSK Medicine Research Centre in Verona, Italy and Senior Site Leader of the New Frontiers Science Park in Harlow, UK.
At GSK, Emiliangelo built an innovative late-stage drug discovery pipeline in depression, anxiety, schizophrenia, addiction-compulsion, sleep disorders, pain, Alzheimer’s and multiple sclerosis involving a number of novel mechanisms that were progressed into the late-stage clinical development. Before this, Emiliangelo was Drug Discovery Director for one of the three GlaxoWellcome Drug Discovery Groups based in Italy and Spain and Research Director of Glaxo Medicine Research Centre in Verona, Italy.
Emiliangelo is passionate about building vibrant and highly productive organizations that are science driven. He embraces multicultural diversity, engaging and empowering people, and fostering external partnerships.
Read more here about Orexia Therapeutics